Portal de Periódicos da CAPES

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

2012; American Association for the Advancement of Science; Volume: 4; Issue: 128 Linguagem: Inglês

10.1126/scitranslmed.3003651

1946-6242

Jeffrey S. Hrkach, Daniel D. Von Hoff, Mir Mukkaram Ali, Elizaveta A. Andrianova, Jason Auer, Tarikh Campbell, David De Witt, Michael Figa, Maria J. Figueiredo, Allen Horhota, Susan C. Low, Kevin McDonnell, Erick Peeke, Beadle Retnarajan, Abhimanyu Sabnis, Edward F. Schnipper, Jeffrey Song, Young Ho Song, Jason M. Summa, Douglas Tompsett, Greg Troiano, Tina Van Geen Hoven, James R. Wright, Patricia LoRusso, Philip W. Kantoff, Neil H. Bander, Christopher Sweeney, Omid C. Farokhzad, Róbert Langer, Stephen E. Zale,

Nanoplatforms for cancer theranostics

A targeted nanoparticle containing docetaxel displays antitumor activity in animals and differentiated pharmacological properties in patients with advanced solid tumors.